Instant MBA type gratification is rarely lasting.
There are plenty of a great things that can be achieved addressing the rare disease space, especially if the Anavex drug(s) work as hoped and eluded to. Nice space for Anavex to potentially own a good slice of all to themselves (and investors).
The challenge now is that the Paediatric Voucher, if we get it, is over a year way now that the EXCELLENCE study completion date has at last been updated to reflect the realistic timing end Dec 2022.
With DB lock, analysis etc. topline will be about end Q1 2023. Packing all the data, incl. co-analysis along with the previous adult Rett studies data will take another good few months.
Probably a Rett all ages NDA filing, like Neuren/ACADIA's just filed, can be around mid 2023. Add six months of FDA processing makes a potential approval and voucher be end 2023 at best to Q1 2024.
Will Anavex file an NDA for AD before then...and forfeit the voucher? Or will sweet F'(da)all happen until the voucher is insight?